183 related articles for article (PubMed ID: 28425921)
1. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer.
Franklin O; Jonsson P; Billing O; Lundberg E; Öhlund D; Nyström H; Lundin C; Antti H; Sund M
Ann Surg; 2018 Apr; 267(4):775-781. PubMed ID: 28425921
[TBL] [Abstract][Full Text] [Related]
2. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
3. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study.
Xu J; Cao Z; Liu W; You L; Zhou L; Wang C; Lou W; Sun B; Miao Y; Liu X; Zhang T; Zhao Y
Ann Surg; 2016 Jun; 263(6):1173-9. PubMed ID: 26114496
[TBL] [Abstract][Full Text] [Related]
4. Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now.
Wei L; Yao K; Gan S; Suo Z
Medicine (Baltimore); 2018 Aug; 97(35):e12132. PubMed ID: 30170450
[TBL] [Abstract][Full Text] [Related]
5. Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
Hussein NA; Kholy ZA; Anwar MM; Ahmad MA; Ahmad SM
J Cancer Res Clin Oncol; 2017 Jan; 143(1):83-93. PubMed ID: 27631726
[TBL] [Abstract][Full Text] [Related]
6. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study.
Cao Z; Liu C; Xu J; You L; Wang C; Lou W; Sun B; Miao Y; Liu X; Wang X; Zhang T; Zhao Y
Oncotarget; 2016 Jul; 7(27):41575-41583. PubMed ID: 27223429
[TBL] [Abstract][Full Text] [Related]
7. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer.
Liu J; Gao J; Du Y; Li Z; Ren Y; Gu J; Wang X; Gong Y; Wang W; Kong X
Int J Cancer; 2012 Aug; 131(3):683-91. PubMed ID: 21913185
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
9. Upregulated exosomic miR‑23b‑3p plays regulatory roles in the progression of pancreatic cancer.
Chen D; Wu X; Xia M; Wu F; Ding J; Jiao Y; Zhan Q; An F
Oncol Rep; 2017 Oct; 38(4):2182-2188. PubMed ID: 28849236
[TBL] [Abstract][Full Text] [Related]
10. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients.
Choe JW; Kim JS; Kim HJ; Hwang SY; Joo MK; Lee BJ; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT
Pancreas; 2016; 45(5):730-4. PubMed ID: 26646277
[TBL] [Abstract][Full Text] [Related]
11. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
[TBL] [Abstract][Full Text] [Related]
12. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
Murali Manohar K; Sasikala M; Kvsrr Y; Sunil V; Talukdar R; Murthy H; Ramji C; Rao GV; Pradeep R; Reddy DN
Tumour Biol; 2017 Mar; 39(3):1010428317695018. PubMed ID: 28351309
[TBL] [Abstract][Full Text] [Related]
13. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.
Johansen JS; Calatayud D; Albieri V; Schultz NA; Dehlendorff C; Werner J; Jensen BV; Pfeiffer P; Bojesen SE; Giese N; Nielsen KR; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK
Int J Cancer; 2016 Nov; 139(10):2312-24. PubMed ID: 27464352
[TBL] [Abstract][Full Text] [Related]
14. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
15. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Nolen BM; Brand RE; Prosser D; Velikokhatnaya L; Allen PJ; Zeh HJ; Grizzle WE; Huang Y; Lomakin A; Lokshin AE
PLoS One; 2014; 9(4):e94928. PubMed ID: 24747429
[TBL] [Abstract][Full Text] [Related]
16. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
17. Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer.
Wei Q; Zhang J; Li Z; Wei L; Ren L
Pancreas; 2020 Oct; 49(9):1213-1219. PubMed ID: 32898008
[TBL] [Abstract][Full Text] [Related]
18. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
Yuan W; Tang W; Xie Y; Wang S; Chen Y; Qi J; Qiao Y; Ma J
Oncotarget; 2016 Nov; 7(48):80033-80045. PubMed ID: 27713117
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis.
El-Mesallamy HO; Hamdy NM; Zaghloul AS; Sallam AM
Pancreas; 2013 Jan; 42(1):149-54. PubMed ID: 22617715
[TBL] [Abstract][Full Text] [Related]
20. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
